MANAGED BY

Kenes MP Asia Pte Ltd
20 Kallang Avenue, PICO Creative Centre, Level 2
Singapore 339411
CONTACT US
General Enquiries:
Registration Enquiries:
Abstract Enquiries:
Copyright 2026 SEATS 2026 | All Rights Reserved | Privacy Policy
|
Time |
09:00 – 16:00 (GMT+8) |
|||
|
Venue |
Grand Hyatt Singapore, Residence 6, Level 3 |
|||
|
Format |
Rotating hands-on stations with focused short didactic sessions and practical demonstrations |
|||
|
Introduction |
This hands-on workshop is designed to strengthen both the technical execution and clinical reasoning required for advanced bronchoscopy and interventional pulmonology. Each station combines short expert demonstrations with deliberate practice, troubleshooting, and discussion of indications, safety checks, and complication management |
|||
|
Objectives |
– Develop a structured approach to procedure planning, including indication, airway anatomy, lesion or nodal target, device selection, and rescue strategy. – Improve hands-on familiarity with convex-probe EBUS bronchoscopes, R-EBUS probes, guide sheaths, biopsy tools, cryoprobes, ablative devices, rigid bronchoscopes, and airway stents. – Practice stepwise technical execution with attention to ergonomics, team communication, equipment readiness, and procedural flow. – Recognise pitfalls early and apply practical strategies for bleeding, airway obstruction, pneumothorax risk, device malposition, and loss of target access.
|
|||
|
Target Participants |
Respiratory physicians, interventional pulmonologists, thoracic surgeons, respiratory and thoracic fellows and trainees, intensivists with an interest in advanced bronchoscopy, bronchoscopy nurses, and allied healthcare professionals involved in bronchoscopy services. |
|||
|
Participants Number |
30 pax |
|||
|
Lead Faculty |
Eric D. Tenda Melvin Tay C.K. SS Kho |
|||
|
Faculty |
Regional and international multidisciplinary experts in respiratory medicine and interventional pulmonology |
|||
| Time | 07:30 – 17:00 (GMT+8) | |||
| Venue | Grand Hyatt Singapore, Residence 5, Level 3 | |||
| Format | Interactive, case-based multidisciplinary workshop focused on precision lung cancer care, integrating molecular tumour board discussions, real-world case simulations, and live audience polling. | |||
| Introduction | This workshop focuses on the practical application of molecular profiling in lung cancer, including NGS, liquid biopsy, and minimal residual disease (MRD). Emphasis is placed on translating biomarker data into real-world clinical decision-making across early-stage and advanced disease settings. | |||
| Objectives | – Apply NGS and molecular profiling in lung cancer management
– Interpret ctDNA and MRD results in clinical practice – Integrate biomarker data into treatment decisions – Manage early and advanced NSCLC using precision oncology approaches – Conduct multidisciplinary tumour board (MTB)–style decision-making in clinical scenarios – Discuss real-world challenges in implementing molecular diagnostics in routine practice – Evaluate emerging roles of perioperative and adjuvant biomarker-guided therapies |
|||
| Target Participants | Medical oncologists, thoracic surgeons, pulmonologists, pathologists, radiation oncologists, trainees, and allied health professionals. | |||
| Lead Faculty | Aaron Tan | |||
| Faculty | Regional and international multidisciplinary experts in thoracic oncology and molecular diagnostics. | |||
|
American Samoa |
Gibraltar |
Panama |
|
Andorra |
Greece |
Poland |
|
Antigua and Barbuda |
Greenland |
Portugal |
|
Aruba |
Guam |
Puerto Rico |
|
Australia |
Guyana |
Qatar |
|
Austria |
Hong Kong SAR, China |
Romania |
|
Bahamas, The |
Hungary |
Russian Federation |
|
Bahrain |
Iceland |
San Marino |
|
Barbados |
Ireland |
Saudi Arabia |
|
Belgium |
Isle of Man |
Seychelles |
|
Bermuda |
Israel |
Singapore |
|
British Virgin Islands |
Italy |
Sint Maarten (Dutch part) |
|
Brunei Darussalam |
Japan |
Slovak Republic |
|
Bulgaria |
Korea, Rep. |
Slovenia |
|
Canada |
Kuwait |
Spain |
|
Cayman Islands |
Latvia |
St. Kitts and Nevis |
|
Channel Islands |
Liechtenstein |
St. Martin (French part) |
|
Chile |
Lithuania |
Sweden |
|
Costa Rica |
Luxembourg |
Switzerland |
|
Croatia |
Macao SAR, China |
Taiwan, China |
|
Curaçao |
Malta |
Trinidad and Tobago |
|
Cyprus |
Monaco |
Turks and Caicos Islands |
|
Czechia |
Nauru |
United Arab Emirates |
|
Denmark |
Netherlands |
United Kingdom |
|
Estonia |
New Caledonia |
United States |
|
Faroe Islands |
New Zealand |
Uruguay |
|
Finland |
Northern Mariana Islands |
Virgin Islands (U.S.) |
|
France |
Norway |
|
|
French Polynesia |
Oman |
|
|
Germany |
Palau |
|
|
Afghanistan |
Korea, Dem. People’s Rep |
Somalia |
|
Burkina Faso |
Liberia |
South Sudan |
|
Burundi |
Madagascar |
Sudan |
|
Central African Republic |
Malawi |
Syrian Arab Republic |
|
Chad |
Mali |
Togo |
|
Congo, Dem. Rep |
Mozambique |
Uganda |
|
Eritrea |
Niger |
Yemen, Rep. |
|
Gambia, The |
Rwanda |
|
|
Guinea-Bissau |
Sierra Leone |
|
|
Albania |
Equatorial Guinea |
Moldova |
|
Algeria |
Fiji |
Mongolia |
|
Argentina |
Gabon |
Montenegro |
|
Armenia |
Georgia |
North Macedonia |
|
Azerbaijan |
Grenada |
Paraguay |
|
Belarus |
Guatemala |
Peru |
|
Belize |
Indonesia |
Samoa |
|
Bosnia and Herzegovina |
Iran, Islamic Rep. |
Serbia |
|
Botswana |
Iraq |
South Africa |
|
Brazil |
Jamaica |
St. Lucia |
|
Cabo Verde |
Kazakhstan |
St. Vincent and the Grenadines |
|
China |
Kosovo |
Suriname |
|
Colombia |
Libya |
Thailand |
|
Cuba |
Malaysia |
Tonga |
|
Dominica |
Maldives |
Türkiye |
|
Dominican Republic |
Marshall Islands |
Turkmenistan |
|
Ecuador |
Mauritius |
Tuvalu |
|
El Salvador |
Mexico |
Ukraine |
|
Angola |
India |
Papua New Guinea |
|
Bangladesh |
Jordan |
Philippines |
|
Benin |
Kenya |
São Tomé and Principe |
|
Bhutan |
Kiribati |
Senegal |
|
Bolivia |
Kyrgyz Republic |
Solomon Islands |
|
Cambodia |
Lao PDR |
Sri Lanka |
|
Cameroon |
Lebanon |
Tajikistan |
|
Comoros |
Lesotho |
Tanzania |
|
Congo, Rep. |
Mauritania |
Timor-Leste |
|
Côte d’Ivoire |
Micronesia, Fed. Sts. |
Tunisia |
|
Djibouti |
Morocco |
Uzbekistan |
|
Egypt, Arab Rep. |
Myanmar |
Vanuatu |
|
Eswatini |
Namibia |
Viet Nam |
|
Ghana |
Nepal |
West Bank and Gaza |
|
Guinea |
Nicaragua |
Zambia |
|
Haiti |
Nigeria |
Zimbabwe |
|
Honduras |
Pakistan |
|
FORCE MAJEURE
The organisers of SEATS 2026 shall not be liable for any delay, modification, postponement, or cancellation of the Event arising from circumstances beyond their reasonable control (“Force Majeure”).
Force Majeure includes, without limitation: war, terrorism, civil unrest or military action; natural disasters (including earthquakes, volcanic eruptions, and severe weather events); governmental or regulatory actions or restrictions; infectious disease outbreaks (including COVID-19, SARS, and MERS); visa refusals or delays; explosions; transport disruptions; airline insolvency; and any other event beyond the organisers’ reasonable control. For the avoidance of doubt, insufficient in-person attendance rendering the Event commercially or operationally unviable shall also constitute Force Majeure.
If the Event cannot be held in person due to Force Majeure, the organisers reserve the right to convert the Event to a fully virtual format or otherwise modify the format, programme, or delivery of the Event as deemed necessary. The organisers shall use reasonable endeavours to deliver the Event in a manner that is safe, practicable, and consistent with its objectives.
In such circumstances, all confirmed registrations shall remain valid for the revised format of the Event.
REFUNDS AND FINANCIAL LIABILITY
In the event of cancellation, postponement, or conversion to a virtual format due to Force Majeure, the organisers shall not be liable for any losses, damages, costs, or expenses incurred by delegates, including but not limited to travel or accommodation expenses.

